Table 1. Summary of the used antibodies, scoring systems and cut-offs.
| Biomarker | Clone | Dilution | Company | Scoring System | |
|---|---|---|---|---|---|
| Positive | Negative | ||||
| ER | 1D5 | 1:500 | Dako | >1% | <1% |
| PR | PGR636 | 1:100 | Dako | >1% | <1% |
| AR | AR441 | 1:300 | Abcam | >1% | <1% |
| HER2 | SP3 | 1:50 | Epitomics | 3+ | 0, 1+ |
| EGFR | EP38Y | 1:50 | Thermo Scientific | 1+, 2+, 3+ | 0 |
| HSP70* | C9F3A-5 | 1:50 | Enzo Life Sciences | 2+, 3+ | 0, 1+ |
| HSP90* | Polyclonal | 1:125 | Cell Signaling technology | 2+, 3+ | 0, 1+ |
| PTEN* | 6H2.1 | 1:100 | Dako | 2 | 0, 1 |
*
Validated at MSKCC, ER estrogen receptor, PR progesterone receptor, AR androgen receptor, HER2 human epidermal growth factor receptor 2, EGFR epidermal growth factor receptor 2, PTEN phosphatase and tensin homolog